Invasive Ductal Carcinoma: Pathology, Markers, and Subtypes

Invasive Ductal Carcinoma (IDC) Features

Invasive ductal carcinoma (IDC) is the most common form of breast cancer. Key pathological features include:

• Invasion: Cancer cells infiltrate the stroma, lacking a myoepithelial layer (confirmed by immunohistochemistry).
• Tumor Cells: Malignant cells characterized by pleomorphism, hyperchromatic nuclei, and mitotic activity.
• Tubule Formation: Varies by grade, ranging from Grade 1 (well-differentiated) to Grade 3 (poorly differentiated).
• Nuclear Grade: Low-grade tumors show small, uniform nuclei, while high-grade tumors exhibit large, irregular, hyperchromatic nuclei.
• Desmoplastic Stroma: Dense fibrous tissue surrounding tumor cells.
• Lymphovascular Invasion: Presence of tumor emboli in lymphatic or vascular channels.
• Necrosis/Calcifications: Frequently observed in high-grade tumors.
• Receptor Status: ER, PR, HER2, and Ki-67 are assessed to determine prognosis and treatment plans.

Tumor Markers in Breast Cancer: ER, PR, and HER2

• Estrogen Receptor (ER): Indicates if the tumor grows in response to estrogen. Significance: ER-positive tumors are likely to respond to hormonal therapies like tamoxifen or aromatase inhibitors, improving prognosis.
• Progesterone Receptor (PR): Shows if the tumor is also influenced by progesterone. Significance: PR-positive tumors often accompany ER-positive ones, further supporting hormonal therapy responsiveness.
• HER2 (Human Epidermal Growth Factor Receptor 2): A protein that promotes cell growth. Overexpression suggests aggressive tumor behavior. Significance: HER2-positive cancers respond to targeted therapies like trastuzumab (Herceptin), improving survival rates.

Overall Importance: Testing for ER, PR, and HER2 helps classify breast cancer, predict prognosis, and determine treatment strategies, ensuring personalized therapy.

Differential Diagnosis of Breast Lumps

A breast lump can have various causes:

• Fibroadenoma: Smooth, mobile lump; confirmed by ultrasound.
• Cyst: Tender, fluid-filled lump; drained for diagnosis.
• Fat Necrosis: Firm lump after injury; imaging shows damaged fat.
• Abscess: Painful, red lump with fever; confirmed by pus drainage.
• Phyllodes Tumor: Fast-growing lump; biopsy required.
• Breast Cancer: Hard, irregular lump with skin or nipple changes; confirmed by imaging and biopsy.
• Mastitis: Painful, red swelling in breastfeeding women; clinical diagnosis.
• Lipoma: Soft, mobile lump; harmless fat, confirmed by imaging.

Diagnosis relies on physical examination, imaging, and biopsy.

Molecular Subtypes of Breast Cancer

Breast cancer is classified into molecular subtypes based on ER, PR, HER2, and Ki-67 levels:

• Luminal A: ER/PR-positive, HER2-negative, low Ki-67. Least aggressive, good prognosis, responds to hormonal therapy.
• Luminal B: ER/PR-positive, HER2-variable, high Ki-67. More aggressive, may require chemotherapy alongside hormonal therapy.
• HER2-Enriched: ER/PR-negative, HER2-positive. Aggressive, responds to HER2-targeted treatments.
• Triple-Negative/Basal-Like: ER/PR-negative, HER2-negative. Very aggressive, treated with chemotherapy, poor prognosis.

Importance: Subtyping helps determine treatment and predict outcomes for breast cancer patients.